Vertex Pain Drug Fails to Outperform Placebo in Key Study, Raising Concerns

Vertex Pharmaceuticals' suzetrigine showed pain reduction but did not surpass placebo results in a Phase 2 trial, leading to a sharp drop in its stock value.